ArticleJournal of hepatocellular carcinoma2025
Efficacy and Safety of Transarterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib for Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven: A Multicentre, Retrospective Propensity Score Matching Analysis.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Safety and Efficacy of TACE-HAIC Combined with Lenvatinib and PD-1 Inhibitors in Large Intermediate-Stage Hepatocellular Carcinoma: A Multi-Center Retrospective Study.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous LAUNCH trial revealed the promising effectiveness of transarterial chemoembolization (TACE) combined with lenvatinib for advanced hepatocellular carcinoma (HCC). However, most intermediate-stage HCC exceeds the up-to-seven criteria, limiting their potential TACE benefits. Hepatic arterial infusion chemotherapy (HAIC) was widely endorsed for delivering substantial survival benefits for high tumor burden HCC, outperforming TACE. Accordingly, we undertook this study to evaluate the efficacy and safety of TACE combined with HAIC plus lenvatinib for intermediate-stage HCC beyond up-to-seven criteria. Methods: From June 2017 to November 2021, clinical data of intermediate-stage HCC patients beyond up-to-seven criteria received TACE combined with HAIC plus lenvatinib or TACE alone from four medical centers in China were retrospectively collected. Propensity score matching (PSM) and inverse probability weighting (IPTW) were applied to balance baseline differences. The Kaplan-Meier method was utilized for survival analysis. Cox regression-based multivariate analysis was used to identify survival-related risk factors. We compare tumor response and the incidence of adverse reactions between groups. Results: A total of 294 intermediate-stage HCC patients beyond up-to-seven criteria received TACE combined with HAIC plus lenvatinib (the TACEHL group, n = 127) or TACE monotherapy (the TACE group, n = 167) were finally enrolled. Following propensity matching, the median OS and median PFS in the TACEHL group were 34.6 months and 15.7 months, respectively, significantly higher than the 15.7 months and 6.9 months observed in the TACE group. In tumor response, the ORR was 71.4% in the TACEHL group and 30.8% in the TACE group (P < 0.001), the DCR was 92.3% in the TACEHL group and 75.8% in the TACE group (P = 0.005). The 3-4 grade adverse reactions were comparable between the groups. Conclusion: For intermediate-stage HCC beyond up-to-seven criteria, the integration of TACE and HAIC plus lenvatinib therapy demonstrated substantial enhancements in survival prognosis, which is a promising treatment regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.